Aequus Pharmaceuticals Inc.

OTCPK:AQSZ.F Stock Report

Market Cap: US$462.1k

Aequus Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Aequus Pharmaceuticals's earnings have been declining at an average annual rate of -7.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 24.6% per year.

Key information

-7.4%

Earnings growth rate

6.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-24.6%
Return on equityn/a
Net Margin-647.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Aequus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:AQSZ.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-330
30 Jun 240-330
31 Mar 240-330
31 Dec 230-330
30 Sep 231-330
30 Jun 231-330
31 Mar 231-330
31 Dec 221-340
30 Sep 222-340
30 Jun 222-240
31 Mar 223-240
31 Dec 213-240
30 Sep 213-240
30 Jun 213-240
31 Mar 213-130
31 Dec 203-130
30 Sep 202-230
30 Jun 202-230
31 Mar 202-340
31 Dec 192-340
30 Sep 191-340
30 Jun 191-340
31 Mar 191-340
31 Dec 181-341
30 Sep 182-340
30 Jun 181-341
31 Mar 181-441
31 Dec 171-441
30 Sep 171-442
30 Jun 171-542
31 Mar 171-541
31 Dec 161-541
30 Sep 161-541
30 Jun 160-542
31 Mar 160-532
31 Dec 150-532
30 Sep 150-532
30 Jun 150-422
31 Mar 150-321
31 Dec 140-211
30 Sep 140-111

Quality Earnings: AQSZ.F is currently unprofitable.

Growing Profit Margin: AQSZ.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AQSZ.F is unprofitable, and losses have increased over the past 5 years at a rate of 7.4% per year.

Accelerating Growth: Unable to compare AQSZ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AQSZ.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: AQSZ.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 10:26
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aequus Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan CaliNOBLE Capital Markets, Inc.